[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541218":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":69,"collaborators":71,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":42,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"University of California, Los Angeles","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Post-CABG patients with Thiamine Treatment Intervention.","EXPERIMENTAL","Assess cognition and evaluate blood thiamine, lactate, and inflammatory marker levels in patients receiving thiamine intervention treatment within 5 days (baseline) and one month after CABG.",[13],"Drug: Thiamine",{"label":15,"type":16,"description":17,"interventionNames":18},"Post-CABG patients without Thiamine Treatment Intervention.","PLACEBO_COMPARATOR","Assess cognition and evaluate blood thiamine, lactate, and inflammatory marker levels in patients receiving placebo treatment within 5 days (baseline) and one month after CABG.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Thiamine","Participants will be given an infusion of thiamine.",[9],[27],"Vitamin B1",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Participants will be given an infusion of the placebo treatment.",[15],[33],"inactive",[35],{"name":36,"affiliation":5,"role":37},"Rajesh Kumar, PhD","PRINCIPAL_INVESTIGATOR",[39,44],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","310-206-1699",null,"rkumar@mednet.ucla.edu",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Dineth Karunamuni, MS","856-701-5332","dkarunamuni@mednet.ucla.edu",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"UCLA","RECRUITING","Los Angeles","California","90095","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-118.24368,34.05223,{"lat":61,"lon":60},[64,67,68],{"name":65,"role":40,"phone":66,"phoneExt":42,"email":43},"Rajesh Kumar, PHD","310-825-1808",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},{"name":65,"role":37,"phone":42,"phoneExt":42,"email":42},{"type":37,"investigatorFullName":36,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Professor of Anesthesiology and Radiological Sciences",[72],{"name":73,"class":74},"National Institute on Aging (NIA)","NIH","100541218","early-phase-1-thiamine-intervention-and-coronary-artery-bypass-grafting-100541218",false,"NCT06326996","Thiamine Intervention and Coronary Artery Bypass Grafting","Thiamine Intervention and Cognition in Older Adults Undergoing Coronary Artery Bypass Grafting - A Randomized Clinical Trial.","B1&CABG","Inclusion Criteria:\n\n* Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)\n* Thiamine deficiency before CABG\n* European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) \\>1.5%\n* Off-pump surgery\n\nExclusion Criteria:\n\n* Dementia at baseline \\[Montreal Cognitive Assessment (MoCA) \\\u003C21 within 5 days before CABG\\]\n* Current in-take of thiamine\n* Known thiamine allergy\n* Uncontrolled blood glucose levels\n* Unable to give consent due to illness\n* History of hyperlactatemia\n* Recent (within several years and\u002For up to the judgment of the PI\u002Fco-PIs) cerebral incidents (seizure or head trauma resulting in loss of consciousness and\u002For concussion)\n* Stroke\n* Diagnosed psychiatric diseases (clinical depression, schizophrenia, manic-depression)\n* Patients with history of alcohol or substance abuse\n* Acute or chronic infections (tuberculosis, hepatitis, or encephalopathy)\n* Diagnosed neuro-degenerative diseases (Alzheimer's or Parkinson's disease)\n* Chronic immunodeficiency (including HIV)\n* Congenital brain deficits will also be excluded","ALL","60 Years","80 Years",{"count":87,"type":88},52,"ESTIMATED","INTERVENTIONAL",[91],"EARLY_PHASE1","The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.",[94,95],"Coronary Heart Disease","Coronary Artery Bypass Grafting",[97],"thiamine intervention","2025-07-30",{"date":100,"type":101},"2025-08-01","ACTUAL",{"date":103,"type":101},"2024-10-10",{"date":105,"type":88},"2026-09-30",{"name":5,"class":6},1]